Company: INTS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001567264-25-000039
Chunk: 14

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
Item 1. Condensed Financial Statements

INTENSITY THERAPEUTICS, INC.

CONDENSED BALANCE SHEETS

(in thousands, except share and per share amounts)

March 31,2025December 31,2024(Unaudited)*ASSETSCurrent assets:Cash and cash equivalents$929 $2,590 Prepaid expenses and other current assets722 773 Total current assets1,651 3,363 Right-of-use asset, net116 122 Other assets1,298 1,298 Total assets$3,065 $4,783 LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable$1,586 $1,219 Accrued expenses1,014 508 Lease liability, current portion29 28 Total current liabilities2,629 1,755 Lease liability, long-term portion102 110 Total liabilities2,731 1,865 Commitments and contingenciesStockholders' equity:Preferred stock, par value $.0001. Authorized shares of 15,000,000 as of both March 31, 2025 and December 31, 2024. None issued and outstanding as of both March 31, 2025 and December 31, 2024.— — Common stock, par value $.0001. Authorized shares of 135,000,000 as of March 31, 2025 and December 31, 2024, respectively. Issued and outstanding shares of 15,264,869 and 15,122,873 as of March 31, 2025 and December 31, 2024, respectively.2 2 Additional paid-in capital70,462 69,699 Accumulated deficit(70,130)(66,783)Total stockholders’ equity334 2,918 Total liabilities and stockholders’ equity$3,065 $4,783 

*Derived from audited financial statements

The accompanying notes are an integral part of these condensed financial statements.

1

Table of Contents

INTENSITY THERAPEUTICS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

(Unaudited)

Three Months Ended March 31,20252024Operating expenses:Research and development$2,189 $2,815 General and administrative1,205 1,928 Total operating expenses